$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

Neurocognitive effects of melatonin treatment in healthy adults and individuals with Alzheimer’s disease and insomnia: A systematic review and meta-analysis of randomized controlled trials 원문보기

Neuroscience and biobehavioral reviews, v.127, 2021년, pp.459 - 473  

Sumsuzzman, Dewan Md. (Department of Rehabilitation Science, Graduate School of Inje University) ,  Choi, Jeonghyun (Department of Rehabilitation Science, Graduate School of Inje University) ,  Jin, Yunho (Biohealth Products Research Center (BPRC), Inje University) ,  Hong, Yonggeun (Department of Rehabilitation Science, Graduate School of Inje University)

Abstract AI-Helper 아이콘AI-Helper

Abstract Endogenous melatonin levels are inversely associated with age and cognitive deficits. Although melatonin can improve psychopathological behavior disturbances in clinical trials, whether melatonin may also enhance cognitive function remains elusive. This study examined cognitive outcomes fr...

주제어

참고문헌 (113)

  1. American Psychiatric Association 1994 American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 

  2. American Psychiatric Association 2000 Diagnostic and Statistical Manual of Mental Disorders 

  3. American Psychiatric Association 2013 The Diagnostic and Statistical Manual of Mental Disorders: DSM-5 

  4. J. Nippon Med. Sch. Asayama 70 334 2003 10.1272/jnms.70.334 Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia 

  5. Ergonomics Atkinson 48 1512 2005 10.1080/00140130500100967 Effects of daytime ingestion of melatonin on short-term athletic performance 

  6. Neurosci. Biobehav. Rev. Bäckman 30 791 2006 10.1016/j.neubiorev.2006.06.005 The correlative triad among aging, dopamine, and cognition: current status and future prospects 

  7. Lancet (London, England) Bixler 337 827 1991 10.1016/0140-6736(91)92524-6 Next-day memory impairment with triazolam use 

  8. Front. Endocrinol. (Lausanne) Cardinali 10 2019 Melatonin: clinical perspectives in neurodegeneration 

  9. Neuroendocrinol. Lett. Cardinali 23 Suppl 1 20 2002 The use of melatonin in Alzheimer’s disease 

  10. Antioxidants Cardinali 3 245 2014 10.3390/antiox3020245 Melatonin therapy in patients with alzheimer’s disease 

  11. Lancet. Public Heal. Chang 4 e159 2019 10.1016/S2468-2667(19)30019-2 Measuring population ageing: an analysis of the Global Burden of Disease Study 2017 

  12. Br. J. Clin. Pharmacol. Chavant 72 898 2011 10.1111/j.1365-2125.2011.04009.x Memory disorders associated with consumption of drugs: updating through a case/noncase study in the French PharmacoVigilance Database 

  13. Behav. Neurol. Chowdhury 2016 1 2016 10.1155/2016/3730940 The effect of chronic alprazolam intake on memory, attention, and psychomotor performance in healthy human male volunteers 

  14. Biol. Psychiatry Claustrat 32 705 1992 10.1016/0006-3223(92)90300-O Melatonin and jet lag: confirmatory result using a simplified protocol 

  15. Eur. J. Clin. Pharmacol. Clay 69 1 2013 10.1007/s00228-012-1424-1 Contribution of prolonged-release melatonin and anti-benzodiazepine campaigns to the reduction of benzodiazepine and z-drugs consumption in nine European countries 

  16. Front. Pharmacol. Cordone 10 2019 Sleep and β-Amyloid deposition in alzheimer disease: insights on mechanisms and possible innovative treatments 

  17. Psychopharmacology (Berl.) Crowley 225 825 2013 10.1007/s00213-012-2869-8 Melatonin in the afternoons of a gradually advancing sleep schedule enhances the circadian rhythm phase advance 

  18. Deeks, J.J., Higgins, J.P.T., Altman, D.G., 2011a. https://handbook-5-1.cochrane.org/chapter_9/9_2_3_1_the_mean_difference_or_difference_in_means.htm (accessed 13 May 2020). 

  19. Deeks, J.J., Higgins, J.P.T., Altman, D.G., 2011b. https://handbook-5-1.cochrane.org/chapter_9/9_2_3_2_the_standardized_mean_difference.htm (accessed 13 May 2020). 

  20. Deeks, J.J., Higgins, J.P.T., Altman, D.G., 2011c. https://handbook-5-1.cochrane.org/chapter_9/9_6_3_1_is_the_effect_different_in_different_subgroups.htm (accessed 13 May 2020). 

  21. Deeks, J.J., Higgins, J.P.T., Altman, D.G., 2011d.https://handbook-5-1.cochrane.org/chapter_9/9_analysing_data_and_undertaking_meta_analyses.htm (accessed 13 May 2020). 

  22. Deeks, J.J., Higgins, J.P.T., Altman, D.G., 2011e. https://handbook-5-1.cochrane.org/chapter_9/9_4_5_2_meta_analysis_of_change_scores.htm (accessed 13 May 2020). 

  23. Psychopharmacology (Berl.) Dollins 112 490 1993 10.1007/BF02244899 Effect of pharmacological daytime doses of melatonin on human mood and performance 

  24. Proc. Natl. Acad. Sci. U. S. A. Dollins 91 1824 1994 10.1073/pnas.91.5.1824 Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance 

  25. J. Am. Geriatr. Soc. Dowling 56 239 2008 10.1111/j.1532-5415.2007.01543.x Melatonin and bright-light treatment for rest-activity disruption in institutionalized patients with Alzheimer’s disease 

  26. Sleep Med. Clin. Eastman 4 241 2009 10.1016/j.jsmc.2009.02.006 How to travel the world without jet lag 

  27. Front. Aging Neurosci. Ettcheto 11 2020 Benzodiazepines and related drugs as a risk factor in alzheimer’s disease dementia 

  28. PLoS One Ferracioli-Oda 8 2013 10.1371/journal.pone.0063773 Meta-analysis: melatonin for the treatment of primary sleep disorders 

  29. J. Clin. Epidemiol. Follmann 45 769 1992 10.1016/0895-4356(92)90054-Q Variance imputation for overviews of clinical trials with continuous response 

  30. Sleep Fortier-Brochu 37 1787 2014 10.5665/sleep.4172 Cognitive impairment in individuals with insomnia: clinical significance and correlates 

  31. Pract. Geriatrics Gao 23 56 2009 Effect of Melatonin on Mild Alzheimer’S Disease in Elderly Male Patients 

  32. Am. J. Geriatr. Psychiatry Off. J. Am. Assoc. Geriatr. Psychiatry Gehrman 17 166 2009 10.1097/JGP.0b013e318187de18 Melatonin fails to improve sleep or agitation in double-blind randomized placebo-controlled trial of institutionalized patients with Alzheimer disease 

  33. Ann. Pharmacother. Ghaeli 52 949 2018 10.1177/1060028018776608 Comparison of the effects of melatonin and oxazepam on anxiety levels and sleep quality in patients with ST-Segment-Elevation myocardial infarction following primary percutaneous coronary intervention: a randomized clinical trial 

  34. BMJ Glass 331 1169 2005 10.1136/bmj.38623.768588.47 Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits 

  35. J. Pineal Res. Gorfine 43 336 2007 10.1111/j.1600-079X.2007.00482.x Nap and melatonin-induced changes in hippocampal activation and their role in verbal memory consolidation 

  36. J. Pineal Res. Gorfine 43 80 2007 10.1111/j.1600-079X.2007.00446.x Melatonin and the human hippocampus, a time dependent interplay 

  37. Alzheimers Res. Ther. Grau-Rivera 12 4 2020 10.1186/s13195-019-0547-3 Association between insomnia and cognitive performance, gray matter volume, and white matter microstructure in cognitively unimpaired adults 

  38. BMJ Gray 352 i90 2016 10.1136/bmj.i90 Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study 

  39. J. Clin. Med. Guina 7 17 2018 10.3390/jcm7020017 Benzodiazepines I: upping the care on downers: the evidence of risks, benefits and alternatives 

  40. Eur. J. Ageing Haimov 3 107 2006 10.1007/s10433-006-0026-0 Association between memory impairment and insomnia among older adults 

  41. Clin. Geriatr. Med. Harada 29 737 2013 10.1016/j.cger.2013.07.002 Normal cognitive aging 

  42. Neurosci. Biobehav. Rev. Hardeland 17 347 1993 10.1016/S0149-7634(05)80016-8 The significance of the metabolism of the neurohormone melatonin: antioxidative protection and formation of bioactive substances 

  43. He 175 2016 An Aging World: 2015 International Population Reports 

  44. J. Clin. Neurol. He 15 9 2019 10.3988/jcn.2019.15.1.9 Risk of dementia in long-term benzodiazepine users: evidence from a meta-analysis of observational studies 

  45. Nervenarzt Helmchen 69 369 1998 10.1007/s001150050285 [Normal and pathological cognitive aging] 

  46. Higgins 187 2008 Cochrane Handbook for Systematic Reviews of Interventions Assessing risk of bias in included studies 

  47. BMJ Higgins 327 557 2003 10.1136/bmj.327.7414.557 Measuring inconsistency in meta-analyses 

  48. Higgins, J.P.T., Deeks, J.J., Altman, D.G., 2011a. https://handbook-5-1.cochrane.org/chapter_16/16_5_4_how_to_include_multiple_groups_from_one_study.htm (accessed 13 May 2020). 

  49. Higgins, J.P.T., Deeks, J.J., Altman, D.G., 2011b. Imputing standard deviations. https://handbook-5-1.cochrane.org/chapter_16/16_1_3_1imputing_standard_deviations.htm (accessed 13 May 2020). 

  50. Higgins, J.P.T., Deeks, J.J., Altman, D.G., 2011c. https://handbook-5-1.cochrane.org/chapter_16/16_1_3_2_imputing_standard_deviations_for_changes_from_baseline.htm (accessed 13 May 2020). 

  51. Higgins, J.P.T., Deeks, J.J., Altman, D.G., 2011d. https://handbook-5-1.cochrane.org/chapter_16/16_4_5_methods_for_incorporating_cross_over_trials_into_a.htm (Accessed 13 May 2020). 

  52. Higgins, J.P.T., Deeks, J.J., Altman, D.G., 2011e. https://handbook-5-1.cochrane.org/chapter_16/16_4_6_2_standardized_mean_difference.htm (Accessed 13 May 2020). 

  53. Alzheimers Dement. Hobart 9 S4 2013 10.1016/j.jalz.2012.08.005 Putting the Alzheimer’s cognitive test to the test I: traditional psychometric methods 

  54. CMAJ Holbrook 162 225 2000 Meta-analysis of benzodiazepine use in the treatment of insomnia 

  55. Mol. Neurobiol. Hossain 56 2019 Melatonin in alzheimer’s disease: a latent endogenous regulator of neurogenesis to mitigate alzheimer’s neuropathology 

  56. Cochrane Database Syst. Rev. Jansen 2006 10.1002/14651858.CD003802.pub3 Melatonin for the treatment of dementia 

  57. J. Pineal Res. Jean-Louis 25 177 1998 10.1111/j.1600-079X.1998.tb00557.x Melatonin effects on sleep, mood, and cognition in elderly with mild cognitive impairment 

  58. J. Rheumatol. Juby 18 354 1991 Specificity, sensitivity and diagnostic predictive value of selected laboratory generated autoantibody profiles in patients with connective tissue diseases 

  59. Psychopharmacology (Berl.) Kamboj 188 482 2006 10.1007/s00213-006-0552-7 Neutral and emotional episodic memory: global impairment after lorazepam or scopolamine 

  60. World Psychiatry Krystal 18 337 2019 10.1002/wps.20674 The assessment and management of insomnia: an update 

  61. A Narrative Review. J Alzheimers Dis Kueper 63 423 2018 10.3233/JAD-170991 The alzheimer’s disease assessment scale-cognitive subscale (ADAS-Cog): modifications and responsiveness in Pre-Dementia populations 

  62. Expert Opin. Pharmacother. Lemoine 13 895 2012 10.1517/14656566.2012.667076 Prolonged-release formulation of melatonin (Circadin) for the treatment of insomnia 

  63. J. Sleep Res. Leufkens 18 387 2009 10.1111/j.1365-2869.2009.00746.x Highway driving performance and cognitive functioning the morning after bedtime and middle-of-the-night use of gaboxadol, zopiclone and zolpidem 

  64. J. Psychiatr. Res. Lieberman 17 135 1982 10.1016/0022-3956(82)90015-2 Mood, performance, and pain sensitivity: changes induced by food constituents 

  65. Brain Res. Lieberman 323 201 1984 10.1016/0006-8993(84)90290-7 Effects of melatonin on human mood and performance 

  66. J. Pineal Res. e12583. Lok 2019 10.1111/jpi.12583 Daytime melatonin and light independently affect human alertness and body temperature 

  67. Neurosci. Biobehav. Rev. Lowe 80 586 2017 10.1016/j.neubiorev.2017.07.010 The neurocognitive consequences of sleep restriction: a meta-analytic review 

  68. J. Pineal Res. e12578. Luengo 2019 10.1111/jpi.12578 Pharmacological doses of melatonin impede cognitive decline in tau‐related Alzheimer models, once tauopathy is initiated, by restoring the autophagic flux 

  69. Int. Clin. Psychopharmacol. Luthringer 24 239 2009 10.1097/YIC.0b013e32832e9b08 The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia 

  70. J. Pineal Res. Maestroni 14 1 1993 10.1111/j.1600-079X.1993.tb00478.x The immunoneuroendocrine role of melatonin 

  71. Neurology McKhann 34 939 1984 10.1212/WNL.34.7.939 Clinical diagnosis of alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on alzheimer’s disease 

  72. PLoS Med. Moher 6 2009 10.1371/journal.pmed.1000097 Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement 

  73. Eur. Geriatr. Med. Morales-Delgado 9 449 2018 10.1007/s41999-018-0068-9 A randomized placebo-controlled trial evaluating the effect of melatonin on sleep quality in patients with mild-moderate dementia 

  74. Malawi Med. J. J. Med. Assoc. Malawi Mukaka 24 69 2012 Statistics corner: a guide to appropriate use of correlation coefficient in medical research 

  75. Neurosci. Biobehav. Rev. Myers 19 553 1995 10.1016/0149-7634(95)00018-6 Changes in circadian rhythms and sleep quality with aging: mechanisms and interventions 

  76. J. Pineal Res. Nickelsen 6 325 1989 10.1111/j.1600-079X.1989.tb00428.x Influence of subchronic intake of melatonin at various times of the day on fatigue and hormonal levels: a placebo-controlled, double-blind trial 

  77. JAMA Nowell 278 2170 1997 10.1001/jama.1997.03550240060035 Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy 

  78. Biol. Psychiatry Ohashi 45 1646 1999 10.1016/S0006-3223(98)00255-8 Daily rhythm of serum melatonin levels and effect of light exposure in patients with dementia of the Alzheimer’s type 

  79. J. Am. Geriatr. Soc. Osorio 59 559 2011 10.1111/j.1532-5415.2010.03288.x Greater risk of Alzheimer’s disease in older adults with insomnia 

  80. Hum. Psychopharmacol. Otmani 23 693 2008 10.1002/hup.980 Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers 

  81. Syst. Rev. Ouzzani 5 210 2016 10.1186/s13643-016-0384-4 Rayyan-a web and mobile app for systematic reviews 

  82. Sleep Med. Pallesen 15 173 2014 10.1016/j.sleep.2013.10.009 A 10-year trend of insomnia prevalence in the adult Norwegian population 

  83. Aviat. Space Environ. Med. Paul 74 1263 2003 Impact of melatonin, zaleplon, zopiclone, and temazepam on psychomotor performance 

  84. Am. J. Geriatr. Psychiatry Off. J. Am. Assoc. Geriatr. Psychiatry Perneczky 14 139 2006 10.1097/01.JGP.0000192478.82189.a8 Mapping scores onto stages: mini-mental state examination and clinical dementia rating 

  85. J. Am. Geriatr. Soc. Prinz 30 86 1982 10.1111/j.1532-5415.1982.tb01279.x Changes in the sleep and waking EEGs of nondemented and demented elderly subjects 

  86. Neurosci. Biobehav. Rev. Raz 30 730 2006 10.1016/j.neubiorev.2006.07.001 Differential aging of the brain: patterns, cognitive correlates and modifiers 

  87. JAMA Riemersma-van der Lek 299 2642 2008 10.1001/jama.299.22.2642 Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial 

  88. J. Pineal Res. Rogers 25 47 1998 10.1111/j.1600-079X.1998.tb00385.x Effect of daytime oral melatonin administration on neurobehavioral performance in humans 

  89. J. Sleep Res. Rogers 12 207 2003 10.1046/j.1365-2869.2003.00360.x Neurobehavioural performance effects of daytime melatonin and temazepam administration 

  90. Drug Deliv. Rybka 23 814 2016 10.3109/10717544.2014.917343 Antioxidant effect of immediate- versus sustained-release melatonin in type 2 diabetes mellitus and healthy controls 

  91. J. Clin. Pharmacol. Scharf 30 461 1990 10.1002/j.1552-4604.1990.tb03486.x Estazolam and flurazepam: a multicenter, placebo-controlled comparative study in outpatients with insomnia 

  92. Int. J. Geriatr. Psychiatry Serfaty 17 1120 2002 10.1002/gps.760 Double blind randomised placebo controlled trial of low dose melatonin for sleep disorders in dementia 

  93. Sleep Singer 26 893 2003 10.1093/sleep/26.7.893 A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer’s disease 

  94. Brain Res. Skene 528 170 1990 10.1016/0006-8993(90)90214-V Daily variation in the concentration of melatonin and 5-methoxytryptophol in the human pineal gland: effect of age and Alzheimer’s disease 

  95. Curr. Opin. Psychiatry Spira 27 478 2014 10.1097/YCO.0000000000000106 Impact of sleep on the risk of cognitive decline and dementia 

  96. J. Travel Med. Suhner 5 7 1998 10.1111/j.1708-8305.1998.tb00448.x Impact of melatonin on driving performance 

  97. Antioxidants Basel (Basel) Sumsuzzman 9 1196 2020 10.3390/antiox9121196 Protective effects of melatonin against severe burn-induced distant organ injury: a systematic review and meta-analysis of experimental studies 

  98. Ageing Res. Rev. Uddin 60 2020 10.1016/j.arr.2020.101046 Circadian and sleep dysfunction in Alzheimer’s disease 

  99. J. Gerontol. Vitiello 45 M131 1990 10.1093/geronj/45.4.M131 Sleep disturbances in patients with mild-stage Alzheimer’s disease 

  100. Curr. Med. Res. Opin. Wade 23 2597 2007 10.1185/030079907X233098 Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes 

  101. Curr. Med. Res. Opin. Wade 27 87 2011 10.1185/03007995.2010.537317 Prolonged release melatonin in the treatment of primary insomnia: evaluation of the age cut-off for short- and long-term response 

  102. Clin. Interv. Aging Wade 9 947 2014 Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer’s disease: a 6-month, randomized, placebo-controlled, multicenter trial 

  103. J. Evid. Med. Wager 4 130 2011 Ethical issues in preparing and publishing systematic reviews 

  104. Int. J. Geriatr. Psychiatry Wang 32 50 2017 10.1002/gps.4571 Meta-analysis of randomized, double-blind, placebo-controlled trials of melatonin in Alzheimer’s disease 

  105. Clin. Endocrinol. (Oxf). Webb 42 221 1995 10.1111/j.1365-2265.1995.tb01869.x Role of melatonin in health and disease 

  106. Neurosci. Biobehav. Rev. Winsky-Sommerer 97 112 2019 10.1016/j.neubiorev.2018.09.027 Disturbances of sleep quality, timing and structure and their relationship with other neuropsychiatric symptoms in Alzheimer’s disease and schizophrenia: insights from studies in patient populations and animal models 

  107. World Health Organization 2019 Dementia 

  108. Am. J. Geriatr. Psychiatry Wu 17 614 2009 10.1097/JGP.0b013e3181a65210 The association between dementia and long-term use of benzodiazepine in the elderly: nested case-control study using claims data 

  109. Science Xie 342 373 2013 10.1126/science.1241224 Sleep drives metabolite clearance from the adult brain 

  110. Am. J. Alzheimers Dis. Other Demen. Xu 30 439 2015 10.1177/1533317514568005 Melatonin for sleep disorders and cognition in dementia: a meta-analysis of randomized controlled trials 

  111. Med. Sci. Monit. Xu 26 2020 10.12659/MSM.923232 Dietary melatonin therapy alleviates the Lamina cribrosa damages in patients with mild cognitive impairments: a double-blinded, randomized controlled study 

  112. J. Geriatr. Psychiatry Neurol. Yesavage 17 20 2004 10.1177/0891988703261994 Sleep/wake disruption in Alzheimer’s disease: APOE status and longitudinal course 

  113. Neurosci. Biobehav. Rev. Zhong 98 177 2019 10.1016/j.neubiorev.2019.01.013 Roles of aging in sleep 

LOADING...

관련 콘텐츠

오픈액세스(OA) 유형

GOLD(Hybrid)

저자가 APC(Article Processing Charge)를 지불한 논문에 한하여 자유로운 이용이 가능한, hybrid 저널에 출판된 논문

저작권 관리 안내
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로